ECSP22007726A - Análogos de relaxina y métodos para usarlos - Google Patents

Análogos de relaxina y métodos para usarlos

Info

Publication number
ECSP22007726A
ECSP22007726A ECSENADI20227726A ECDI202207726A ECSP22007726A EC SP22007726 A ECSP22007726 A EC SP22007726A EC SENADI20227726 A ECSENADI20227726 A EC SENADI20227726A EC DI202207726 A ECDI202207726 A EC DI202207726A EC SP22007726 A ECSP22007726 A EC SP22007726A
Authority
EC
Ecuador
Prior art keywords
rln
analogs
disclosed
methods
relaxin
Prior art date
Application number
ECSENADI20227726A
Other languages
English (en)
Inventor
Xiaojun Wang
Petra Verdino
Stacey Lynn Lee
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP22007726A publication Critical patent/ECSP22007726A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se divulgan análogos de relaxina (RLN) que incluyen modificaciones que aumentan la semivida en comparación con la RLN humana nativa, que mantienen la selectividad para el receptor RXFP1 y que proporcionan estabilidad in vitro e in vivo para mejorar las propiedades de farmacología y reducir la inmunogenicidad. También se divulgan composiciones farmacéuticas que incluyen uno o más de los análogos de RLN descritos en la presente en un portador aceptable desde el punto de vista farmacéutico. También se divulgan métodos para elaborar y usar los análogos de RLN, en especial para tratar afecciones, enfermedades o trastornos cardiovasculares, pulmonares y/o renales.
ECSENADI20227726A 2019-07-31 2022-01-31 Análogos de relaxina y métodos para usarlos ECSP22007726A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962880968P 2019-07-31 2019-07-31
US202062970005P 2020-02-04 2020-02-04

Publications (1)

Publication Number Publication Date
ECSP22007726A true ECSP22007726A (es) 2022-02-25

Family

ID=72087312

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20227726A ECSP22007726A (es) 2019-07-31 2022-01-31 Análogos de relaxina y métodos para usarlos

Country Status (20)

Country Link
US (3) US12358965B2 (es)
EP (2) EP4004027A1 (es)
JP (3) JP7270105B2 (es)
KR (1) KR102762810B1 (es)
CN (3) CN114174347B (es)
AU (1) AU2020321977C1 (es)
BR (1) BR112022001448A2 (es)
CA (2) CA3144989A1 (es)
CL (1) CL2022000178A1 (es)
CO (1) CO2022000656A2 (es)
CR (1) CR20220021A (es)
DO (1) DOP2022000018A (es)
EC (1) ECSP22007726A (es)
IL (1) IL289464A (es)
JO (1) JOP20220023A1 (es)
MX (1) MX2022001136A (es)
PE (1) PE20220965A1 (es)
PH (1) PH12022550231A1 (es)
TW (2) TW202434620A (es)
WO (2) WO2021022149A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018107117A1 (en) 2016-12-09 2018-06-14 Akston Biosciences Corporation Insulin-fc fusions and methods of use
EP3746467B1 (en) * 2018-01-31 2025-10-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
CN113038964B (zh) 2018-06-29 2025-05-27 德克拉有限公司 超长效胰岛素-fc融合蛋白及使用方法
HUE064376T2 (hu) 2019-12-19 2024-03-28 Akston Biosciences Corp Ultra-hosszú hatású inzulin-FC fúziós fehérjék és felhasználási eljárások
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
KR102898622B1 (ko) 2020-04-10 2025-12-12 악스톤 바이오사이언시스 코퍼레이션 Covid-19 융합 단백질에 대한 항원 특이적 면역요법 및 사용 방법
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
WO2022169757A1 (en) * 2021-02-02 2022-08-11 Eli Lilly And Company Half-life extending moieties and methods of using the same
WO2023004406A2 (en) 2021-07-23 2023-01-26 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
IL312731A (en) 2021-11-11 2024-07-01 Tectonic Therapeutic Inc Relaxin-2 fusion protein analogs and methods of using same
JP2023092810A (ja) * 2021-12-22 2023-07-04 国立大学法人東京農工大学 変異抗体、変異抗体の製造方法
EP4524156A4 (en) 2022-05-07 2025-10-22 Beijing Tuo Jie Biopharmaceutical Co Ltd RELAXIN FUSION PROTEIN OR ANALOGUE AND ITS MEDICAL USE
AU2024270919A1 (en) 2023-05-18 2026-01-15 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same
KR20250054870A (ko) * 2023-10-16 2025-04-24 (주)케어젠 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도
WO2025098472A1 (zh) * 2023-11-08 2025-05-15 北京拓界生物医药科技有限公司 融合蛋白及其医药用途

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835251A (en) 1986-06-23 1989-05-30 Genetech, Inc. Method of chain combination
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5166191A (en) 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
SI0792290T1 (en) 1993-09-17 2001-12-31 Novo Nordisk As Acylated insulin
AU5724996A (en) 1995-05-05 1996-11-21 Eli Lilly And Company Single chain insulin with high bioactivity
EP2107069B1 (en) 2003-08-05 2013-01-16 Novo Nordisk A/S Novel insulin derivatives
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー／エス 単鎖インシュリン
JP2008533100A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｐｅｇ化された単鎖インスリン
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
EP1991575A1 (en) 2006-02-21 2008-11-19 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
JP2009530243A (ja) 2006-03-13 2009-08-27 ノボ・ノルデイスク・エー／エス アシル化単鎖インスリン
US20090069215A1 (en) 2006-03-13 2009-03-12 Novo Nordisk A/S Acylated Single Chain Insulin
WO2007104734A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104736A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
CN101646689A (zh) 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
JP2010505435A (ja) 2006-10-11 2010-02-25 アブリンクス エン．ヴェー． 本質的にｐＨに非依存的に血清タンパク質に結合するアミノ酸配列、それを含む化合物、およびその使用
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
US7888913B1 (en) 2009-09-08 2011-02-15 Intermec Ip Corp. Smart battery charger
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
US20110250215A1 (en) 2010-04-02 2011-10-13 Athena Discovery, Inc. Structurally-related relaxin-fusion proteins with extended in vivo half-lives
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
EP2582719B1 (en) 2010-06-16 2016-08-10 Indiana University Research and Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
SMT201900495T1 (it) 2010-08-17 2019-11-13 Ambrx Inc Polipeptidi di relaxina modificati e loro usi
AU2011301146B2 (en) 2010-09-08 2016-01-21 Howard Florey Institute Of Experimental Physiology And Medicine Single chain relaxin polypeptides
EP3466972B1 (en) 2011-06-23 2026-03-04 Ablynx NV Serum albumin binding proteins
US9382305B2 (en) 2011-07-01 2016-07-05 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
WO2013007563A1 (en) 2011-07-08 2013-01-17 Bayer Intellectual Property Gmbh Fusion proteins releasing relaxin and uses thereof
WO2013177529A1 (en) 2012-05-24 2013-11-28 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
CN103509118B (zh) 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
JP6584953B2 (ja) 2012-11-05 2019-10-02 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 長時間作用型単鎖インスリン類似体
AR094147A1 (es) 2012-12-27 2015-07-15 Bayer Pharma Aktiengellschaft Polipeptidos de fusion con actividad de relaxina y sus usos
SG10201907106VA (en) 2013-02-26 2019-09-27 Hanmi Pharmaceutical Co Ltd Novel insulin analog and use thereof
KR20160071472A (ko) 2013-11-07 2016-06-21 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 인간 릴렉신 유사체, 이의 약제학적 조성물 및 이의 약제학적 적용
US20160296600A1 (en) 2013-11-11 2016-10-13 Ascendis Pharma Relaxin Division A/S Relaxin Prodrugs
AU2015206890B2 (en) 2014-01-20 2019-05-23 Hanmi Pharm. Co., Ltd. Long-acting insulin and use thereof
US10264071B2 (en) 2014-03-31 2019-04-16 Amazon Technologies, Inc. Session management in distributed storage systems
WO2015157829A1 (en) 2014-04-17 2015-10-22 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides
CA2961037A1 (en) 2014-10-06 2016-04-14 Case Western Reserve University Biphasic single-chain insulin analogues
MA41794A (fr) 2015-03-18 2018-01-23 The California Institute For Biomedical Res Agents thérapeutiques modifiés et compositions associées
AR105616A1 (es) * 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
JP6951825B2 (ja) 2015-09-04 2021-10-20 ザ スクリプス リサーチ インスティテュート インスリン免疫グロブリン融合タンパク質
EP3341405A4 (en) 2015-09-24 2019-05-01 Hanmi Pharm. Co., Ltd. PROCESS FOR INSULIN PRODUCTION
ES2905912T3 (es) 2015-11-13 2022-04-12 Ablynx Nv Dominios variables de inmunoglobulina de unión a albúmina sérica mejorados
PT3387019T (pt) * 2015-12-09 2022-01-14 Scripps Research Inst Proteínas de fusão de imunoglobulina de relaxina e métodos de uso
JP7088911B2 (ja) 2016-05-18 2022-06-21 モデルナティエックス インコーポレイテッド リラキシンをコードするポリヌクレオチド
EP3551656A1 (en) 2016-12-07 2019-10-16 Ablynx NV Improved serum albumin binding immunoglobulin single variable domains
JP2020505029A (ja) 2017-01-25 2020-02-20 メディミューン，エルエルシー リラキシン融合ポリペプチドおよびその使用
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
TW201835099A (zh) 2017-03-07 2018-10-01 美國凱斯西方瑞瑟夫大學 藉由第四雙硫鍵穩定之單鏈胰島素類似物
JOP20190273A1 (ar) 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
CN111201246B (zh) 2017-07-11 2023-10-27 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
CA3070253A1 (en) 2017-07-19 2019-01-24 Vib Vzw Serum albumin binding agents
KR20190036956A (ko) 2017-09-28 2019-04-05 한미약품 주식회사 지속형 단쇄 인슐린 아날로그 및 이의 결합체
EP3717508A1 (en) 2017-12-01 2020-10-07 The University of Copenhagen Peptide hormone with one or more o-glycans
CA3098165A1 (en) 2018-04-24 2019-10-31 National Research Council Of Canada Serum albumin binding antibodies for tuneable half-life extension of biologics

Also Published As

Publication number Publication date
AU2020321977C1 (en) 2024-04-18
JP7270105B2 (ja) 2023-05-09
WO2021022149A1 (en) 2021-02-04
IL289464A (en) 2022-02-01
CR20220021A (es) 2022-02-11
CO2022000656A2 (es) 2022-01-28
TW202120536A (zh) 2021-06-01
KR102762810B1 (ko) 2025-02-05
WO2021022139A1 (en) 2021-02-04
TW202434620A (zh) 2024-09-01
CN114174348B (zh) 2025-07-04
US20220275042A1 (en) 2022-09-01
JP2024009827A (ja) 2024-01-23
CN114174348A (zh) 2022-03-11
CL2022000178A1 (es) 2022-11-18
MX2022001136A (es) 2022-02-16
US20260125446A1 (en) 2026-05-07
BR112022001448A2 (pt) 2022-05-17
CN114174347A (zh) 2022-03-11
NZ784645A (en) 2025-09-26
EP4004027A1 (en) 2022-06-01
CA3145491A1 (en) 2021-02-04
CN119161472A (zh) 2024-12-20
JP7748428B2 (ja) 2025-10-02
US12358965B2 (en) 2025-07-15
AU2020321977B2 (en) 2023-10-19
JP2022542301A (ja) 2022-09-30
PE20220965A1 (es) 2022-06-10
JOP20220023A1 (ar) 2023-01-30
KR20220031044A (ko) 2022-03-11
JP7748358B2 (ja) 2025-10-02
JP2022542980A (ja) 2022-10-07
AU2020321977A1 (en) 2022-02-24
CN114174347B (zh) 2024-09-24
CA3144989A1 (en) 2021-02-04
DOP2022000018A (es) 2022-03-15
US20220378931A1 (en) 2022-12-01
EP4004028A1 (en) 2022-06-01
PH12022550231A1 (en) 2023-01-04
TWI844709B (zh) 2024-06-11

Similar Documents

Publication Publication Date Title
DOP2022000018A (es) Análogos de relaxina y métodos para usarlos
CL2021001073A1 (es) Análogos de proteína tirosina-tirosina y métodos de uso de esta
CL2021000972A1 (es) Inhibidores de la proteína tirosina fosfatasa
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
CL2022001111A1 (es) Degradadores de moléculas pequeñas de helios y procedimientos de uso
MX2018014016A (es) Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
CL2016003048A1 (es) Analogos de panonina minimas sintesis y uso de los mismos.
MX2025001943A (es) Derivado de peptido-1 (glp-1) similar al glucagon acilado
CO2021005915A2 (es) Composiciones estables de semaglutida y usos de las mismas
MX2021004185A (es) Polipeptidos analogos de la amilina humana y sus metodos de uso.
DOP2020000192A (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina y usos de estos
CL2021003273A1 (es) Composición farmacéutica parenteral del agonista dual glp1/2
MX2023006811A (es) Compuestos novedosos.
MX2022002437A (es) Metodos para la produccion de arginasa humana recombinante 1 y sus usos.
AR111236A1 (es) Uso intradialítico de tiosulfato de sodio
CL2025003008A1 (es) Fracciones que prolongan la semivida y métodos de uso de estas.
AR119473A1 (es) Análogos de relaxina y métodos para usarlos
JOP20230150A1 (ar) صيغ ببتيد علاجية
PL438696A1 (pl) Związki stanowiące C20-modyfikowane pochodne salinomycyny, sposób ich otrzymywania, kompozycja je zawierająca, zastosowanie tych związków oraz produkty pośrednie jak i sposoby ich otrzymywania
PE20231943A1 (es) Formulacion combinada oral que incluye gemigliptina y dapagliflozina y metodo de preparacion para la misma
TH2201000491A (th) รีแลกซินอนาลอคและวิธีการในการใช้สารดังกล่าว
MX2022003481A (es) Formulaciones liquidas de rifaximina.
AR116803A1 (es) Análogos de proteína tirosina-tirosina y métodos de uso de esta
MX2018007326A (es) Composicion para reducir la frecuencia de miccion, metodo para elaborar y utilizar la misma.